Figure 2From: The evolving clinical profile of abatacept (CTLA4–Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritisPercentage of patients meeting American College of Rheumatology (ACR) 20, ACR 50, and ACR 70 response criteria after 6 months of therapy with abatacept or placebo. From data presented by Kremer and coworkers [3]. *P ≤ 0.05 versus placebo; †P ≤ 0.001 versus placebo.Back to article page